ONCAlert | 2018 Gastrointestinal Cancers Symposium

Acute Myeloid Leukemia MORE >>

Based on findings from a phase I trial presented at the 2017 ASH Annual Meeting, ivosidenib (AG-120) has been granted a priority review designation by the FDA for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.